S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
Log in
NASDAQ:NTRP

Neurotrope Stock Forecast, Price & News

$0.97
+0.03 (+2.85 %)
(As of 11/24/2020 04:33 PM ET)
Add
Compare
Today's Range
$0.92
Now: $0.97▼
$0.98
50-Day Range
$0.92
MA: $1.04▼
$1.12
52-Week Range
$0.68
Now: $0.97▼
$3.85
Volume427,896 shs
Average Volume602,533 shs
Market Capitalization$23.12 million
P/E RatioN/A
Dividend YieldN/A
Beta2.27
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.
Read More
Neurotrope logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.92 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRP
Previous Symbol
CUSIPN/A
CIK1513856
Webwww.neurotropebioscience.com
Phone973-242-0005
Employees5

Debt

Debt-to-Equity RatioN/A
Current Ratio28.88
Quick Ratio28.88

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.33 per share
Price / Book0.73

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-15,140,000.00
Net MarginsN/A
Return on Equity-48.35%
Return on Assets-47.07%

Miscellaneous

Outstanding Shares23,791,000
Market Cap$23.12 million
Next Earnings Date11/24/2020 (Estimated)
OptionableOptionable
$0.97
+0.03 (+2.85 %)
(As of 11/24/2020 04:33 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

How has Neurotrope's stock price been impacted by COVID-19?

Neurotrope's stock was trading at $0.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTRP shares have increased by 12.0% and is now trading at $0.9744.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Neurotrope?

Wall Street analysts have given Neurotrope a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neurotrope wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Neurotrope's next earnings date?

Neurotrope is scheduled to release its next quarterly earnings announcement on Tuesday, November 24th 2020.
View our earnings forecast for Neurotrope.

How were Neurotrope's earnings last quarter?

Neurotrope, Inc. (NASDAQ:NTRP) issued its earnings results on Tuesday, October, 30th. The company reported ($0.40) EPS for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.05.
View Neurotrope's earnings history.

Are investors shorting Neurotrope?

Neurotrope saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 172,700 shares, an increase of 74.3% from the September 30th total of 99,100 shares. Based on an average daily volume of 475,700 shares, the days-to-cover ratio is presently 0.4 days.
View Neurotrope's Short Interest.

Who are some of Neurotrope's key competitors?

Some companies that are related to Neurotrope include Leap Therapeutics (LPTX), NeuroBo Pharmaceuticals (NRBO), Rockwell Medical (RMTI), ProPhase Labs (PRPH), Aravive (ARAV), Capricor Therapeutics (CAPR), Galmed Pharmaceuticals (GLMD), NervGen Pharma (NGENF), Clearside Biomedical (CLSD), American BriVision (Holding) (ABVC), Eyenovia (EYEN), Gemphire Therapeutics (GEMP), Aptorum Group (APM), RegeneRx Biopharmaceuticals (RGRX) and DiaMedica Therapeutics (DMAC).
View all competitors.

What other stocks do shareholders of Neurotrope own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Alibaba Group (BABA), KemPharm (KMPH), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), VistaGen Therapeutics (VTGN), Canopy Growth (CGC) and Intel (INTC).

Who are Neurotrope's key executives?

Neurotrope's management team includes the following people:
  • Dr. Charles S. Ryan J.D., Ph.D., Chief Exec. Officer and Director (Age 56, Pay $850.21k)
  • Dr. Daniel L. Alkon, Pres & Chief Science Officer (Age 78, Pay $275k)
  • Mr. Robert Weinstein, Chief Financial Officer, Exec. VP, Sec. and Treasurer (Age 60, Pay $423.82k)
  • Mr. Jeffrey Benison, Director of Corp. Communications
  • Dr. Alan J. Tuchman, Acting Chief Medical Officer (Age 73)

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

Who are Neurotrope's major shareholders?

Neurotrope's stock is owned by many different retail and institutional investors. Top institutional investors include One68 Global Capital LLC (0.61%), Cambridge Investment Research Advisors Inc. (0.14%) and FNY Investment Advisers LLC (0.11%). Company insiders that own Neurotrope stock include Jonathan Schechter and Joshua Silverman.
View institutional ownership trends for Neurotrope.

Which institutional investors are buying Neurotrope stock?

NTRP stock was bought by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc., FNY Investment Advisers LLC, and One68 Global Capital LLC. Company insiders that have bought Neurotrope stock in the last two years include Jonathan Schechter, and Joshua Silverman.
View insider buying and selling activity for Neurotrope.

How do I buy shares of Neurotrope?

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $0.97.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $23.18 million. Neurotrope employs 5 workers across the globe.

What is Neurotrope's official website?

The official website for Neurotrope is www.neurotropebioscience.com.

How can I contact Neurotrope?

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.